Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

Tumor mutational burden (TMB) is a genomic biomarker that predicts favorable responses to immune checkpoint inhibitors (ICIs). Here, we set out to assess the predictive value of TMB on long-term survival outcomes in patients undergoing ICIs. We systematically searched PubMed, Embase, CENTRAL and cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jong Yeob, Kronbichler, Andreas, Eisenhut, Michael, Hong, Sung Hwi, van der Vliet, Hans J., Kang, Jeonghyun, Shin, Jae Il, Gamerith, Gabriele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895916/
https://www.ncbi.nlm.nih.gov/pubmed/31731749
http://dx.doi.org/10.3390/cancers11111798

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6895916/
https://www.ncbi.nlm.nih.gov/pubmed/31731749
http://dx.doi.org/10.3390/cancers11111798

Ejemplares similares